<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://articlefeeds.nasdaq.com/~d/styles/itemcontent.css"?><rss xmlns:a10="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel xmlns:nasdaq="http://nasdaq.com/reference/feeds/1.0/">
    <title>Latest Articles about FBP</title>
    <description />
    <language>EN-US</language>
    <lastBuildDate>Tue, 21 May 2013 16:03:18 -0400</lastBuildDate>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://articlefeeds.nasdaq.com/nasdaq/symbols?symbol=FBP" /><feedburner:info uri="nasdaq/symbols" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item xml:base="http://www.nasdaq.com/article/15-stocks-that-hit-the-deepvalue-trifecta-cm239079">
      <guid isPermaLink="false">239079</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uaQkMKQhsMk/15-stocks-that-hit-the-deepvalue-trifecta-cm239079</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <title>15 Stocks That Hit The 'Deep-Value Trifecta'</title>
      <description>Value investors tend to favor specific gauges to find bargains. Some like to seek out stocks trading below tangible book value, while others seek out stocks that sport low price-to-earnings&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/uaQkMKQhsMk" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 22 Apr 2013 17:30:00 Z</pubDate>
      <a10:updated>2013-04-22T23:11:11Z</a10:updated>
      <author>davidsterman@streetauthority.com (dsterman)</author>
      <nasdaq:tickers>AHL</nasdaq:tickers>
      <nasdaq:tickers>FBP</nasdaq:tickers>
      <nasdaq:tickers>MET</nasdaq:tickers>
      <nasdaq:tickers>PL</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/15-stocks-that-hit-the-deepvalue-trifecta-cm239079</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/15-stocks-that-hit-the-deepvalue-trifecta-cm239875">
      <guid isPermaLink="false">239875</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1MAeU2B4E6E/15-stocks-that-hit-the-deepvalue-trifecta-cm239875</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <title>15 Stocks That Hit The 'Deep-Value Trifecta'</title>
      <description>Value investors tend to favor specific gauges to find bargains. Some like to seek outstocks trading below tangiblebook value , while others seek out stocks that sport low price-to-earnings (P/E&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/1MAeU2B4E6E" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 22 Apr 2013 16:30:00 Z</pubDate>
      <a10:updated>2013-04-24T05:09:54Z</a10:updated>
      <author>David Sterman</author>
      <nasdaq:tickers>AAWW</nasdaq:tickers>
      <nasdaq:tickers>FBP</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/15-stocks-that-hit-the-deepvalue-trifecta-cm239875</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/galena-biopharma-clinical-programs-remain-on-track-and-valuation-is-attractive-analyst-blog-cm216346">
      <guid isPermaLink="false">216346</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t3ihtemq-MI/galena-biopharma-clinical-programs-remain-on-track-and-valuation-is-attractive-analyst-blog-cm216346</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Galena Biopharma: Clinical Programs Remain on Track and Valuation is Attractive - Analyst Blog</title>
      <description>Galena Biopharma: Clinical Programs Remain on Track and Valuation is Attractive    By Grant Zeng, CFA    Balance Sheet Boosted by New Equity Financing    On December 18, 2012,  Galena&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/t3ihtemq-MI" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 11 Feb 2013 21:45:01 Z</pubDate>
      <a10:updated>2013-02-11T17:50:26Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CG</nasdaq:tickers>
      <nasdaq:tickers>FBP</nasdaq:tickers>
      <nasdaq:tickers>ITT</nasdaq:tickers>
      <nasdaq:tickers>NP</nasdaq:tickers>
      <nasdaq:tickers>VG</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/galena-biopharma-clinical-programs-remain-on-track-and-valuation-is-attractive-analyst-blog-cm216346</feedburner:origLink></item>
  </channel>
</rss>
